CV6 Therapeutics (NI) Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CV6 Therapeutics (NI) Limited - overview
Established
2013
Location
Belfast, -, UK
Primary Industry
Biotechnology
About
Based in Belfast, UK, and founded by Robert Ladner (CEO) in 2013, CV6 Therapeutics (NI) Limited, is a biotechnology company engaged in the development of biopharmaceutical drugs. In November 2022, the firm raised GBP 8 million in venture funding from investors QUBIS Limited, Invest Northern Ireland, CoFund NI, and Techstart Ventures. The company engages in the discovery, early-stage development, and commercialization of small-molecule therapeutics for the treatment of cancer and inflammatory diseases. The company’s product CV6-168, which as of November 2022 is in the IND enabling studies phase, is a DNA uracilation agent that in combination with standard cancer therapies such as thymidylate synthase (TS) inhibitors, does uracil-based DNA damage and cell death.
CV6 Therapeutics’ other CV6-1271 which is in the pre-clinical stage as of November 2022, treats inflammatory conditions. The firm plans to utilize its November 2022 funding to support and progress its CV6-168 into the first-in-human Phase 1a clinical trial in 2023 and to perform further scientific development work.
Current Investors
Clarendon Fund Managers, Invest Northern Ireland, Qubis
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.cv6t.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.